These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 1418864)
21. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451 [TBL] [Abstract][Full Text] [Related]
23. On the reversibility of reversible MAO inhibitors. Waldmeier PC Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283 [TBL] [Abstract][Full Text] [Related]
25. The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat. Rényi L Br J Pharmacol; 1986 Aug; 88(4):827-35. PubMed ID: 3091132 [TBL] [Abstract][Full Text] [Related]
26. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Zimmer R Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084 [TBL] [Abstract][Full Text] [Related]
27. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Zajaczkowski W; Górka Z Pol J Pharmacol; 1993; 45(2):157-66. PubMed ID: 8401768 [TBL] [Abstract][Full Text] [Related]
28. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998 [TBL] [Abstract][Full Text] [Related]
29. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Ramaekers JG; van Veggel LM; O'Hanlon JF Clin Neuropharmacol; 1994; 17 Suppl 1():S9-18. PubMed ID: 7954488 [TBL] [Abstract][Full Text] [Related]
30. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Waldmeier PC Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214 [TBL] [Abstract][Full Text] [Related]
31. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat. Dyck LE; Boulton AA Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274 [TBL] [Abstract][Full Text] [Related]
32. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Murphy DL; Lipper S; Slater S; Shiling D Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Fisar Z; Hroudová J; Raboch J Neuro Endocrinol Lett; 2010; 31(5):645-56. PubMed ID: 21200377 [TBL] [Abstract][Full Text] [Related]
34. Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. Da Prada M; Kettler R; Cesura AM; Richards JG Pharmacol Res Commun; 1988 Dec; 20 Suppl 4():21-33. PubMed ID: 3149747 [No Abstract] [Full Text] [Related]
35. Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics. Cesura AM; Muggli-Maniglio D; Lang G; Imhof R; Da Prada M J Neural Transm Suppl; 1990; 32():165-70. PubMed ID: 2089085 [TBL] [Abstract][Full Text] [Related]
36. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Keller HH; Kettler R; Keller G; Da Prada M Naunyn Schmiedebergs Arch Pharmacol; 1987 Jan; 335(1):12-20. PubMed ID: 3574489 [TBL] [Abstract][Full Text] [Related]
37. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089 [TBL] [Abstract][Full Text] [Related]
38. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770 [TBL] [Abstract][Full Text] [Related]
39. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391 [TBL] [Abstract][Full Text] [Related]
40. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]